JP2019523305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523305A5 JP2019523305A5 JP2019526375A JP2019526375A JP2019523305A5 JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5 JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5
- Authority
- JP
- Japan
- Prior art keywords
- particle size
- tolucapon
- transthyretin
- malvern
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382372.7 | 2016-07-29 | ||
| EP16382372.7A EP3275433A1 (en) | 2016-07-29 | 2016-07-29 | Sustained release composition comprising micronized tolcapone |
| PCT/EP2017/069168 WO2018019997A1 (en) | 2016-07-29 | 2017-07-28 | Sustained release composition comprising micronized tolcapone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523305A JP2019523305A (ja) | 2019-08-22 |
| JP2019523305A5 true JP2019523305A5 (enExample) | 2020-08-13 |
| JP7047236B2 JP7047236B2 (ja) | 2022-04-05 |
Family
ID=56571284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526375A Active JP7047236B2 (ja) | 2016-07-29 | 2017-07-28 | 微粒子化トルカポンを含む徐放性錠剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11883538B2 (enExample) |
| EP (2) | EP3275433A1 (enExample) |
| JP (1) | JP7047236B2 (enExample) |
| KR (1) | KR102484678B1 (enExample) |
| CN (1) | CN109789100A (enExample) |
| AU (1) | AU2017303333B2 (enExample) |
| DK (1) | DK3490535T3 (enExample) |
| ES (1) | ES2891355T3 (enExample) |
| MX (1) | MX391116B (enExample) |
| PT (1) | PT3490535T (enExample) |
| RU (1) | RU2750670C2 (enExample) |
| WO (1) | WO2018019997A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081554A2 (en) * | 2022-10-10 | 2024-04-18 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DE69733752T2 (de) | 1996-05-20 | 2006-06-01 | G.D. Searle Llc, Chicago | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz |
| WO1999052504A1 (en) * | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| CA2510320C (en) * | 2002-12-20 | 2012-10-09 | St. James Associates Llc/Faber Research Series | Coated particles for sustained-release pharmaceutical administration |
| EP2335696A1 (en) * | 2005-06-08 | 2011-06-22 | Orion Corporation | An entacapone-containing oral dosage form |
| WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
| SI2640358T1 (en) * | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| MX355309B (es) | 2011-03-14 | 2018-04-16 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno. |
| WO2013060668A1 (en) * | 2011-10-24 | 2013-05-02 | Som Innovation Biotech, S.L. | New therapy for transthyretin-associated amyloidosis |
| US20130195973A1 (en) * | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| CN105209029A (zh) * | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| ES2957768T3 (es) * | 2013-11-05 | 2024-01-25 | Synagile Corp | Suministro continuo de fármacos a través de la boca |
| CA3175785A1 (en) * | 2014-09-04 | 2016-03-10 | Intrance International Ab | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
-
2016
- 2016-07-29 EP EP16382372.7A patent/EP3275433A1/en not_active Withdrawn
-
2017
- 2017-07-28 CN CN201780060604.7A patent/CN109789100A/zh active Pending
- 2017-07-28 ES ES17743358T patent/ES2891355T3/es active Active
- 2017-07-28 DK DK17743358.8T patent/DK3490535T3/da active
- 2017-07-28 AU AU2017303333A patent/AU2017303333B2/en active Active
- 2017-07-28 WO PCT/EP2017/069168 patent/WO2018019997A1/en not_active Ceased
- 2017-07-28 EP EP17743358.8A patent/EP3490535B1/en active Active
- 2017-07-28 PT PT177433588T patent/PT3490535T/pt unknown
- 2017-07-28 MX MX2019001190A patent/MX391116B/es unknown
- 2017-07-28 RU RU2019103647A patent/RU2750670C2/ru active
- 2017-07-28 KR KR1020197004664A patent/KR102484678B1/ko active Active
- 2017-07-28 US US16/321,336 patent/US11883538B2/en active Active
- 2017-07-28 JP JP2019526375A patent/JP7047236B2/ja active Active
-
2024
- 2024-01-29 US US18/425,739 patent/US12220487B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015096530A5 (enExample) | ||
| JP2015525757A5 (enExample) | ||
| HK1220472A1 (zh) | 神经活性类固醇、组合物、及其用途 | |
| JP2012143233A5 (enExample) | ||
| JP2019508789A5 (enExample) | ||
| JP2014237817A5 (enExample) | ||
| JP2014530840A5 (enExample) | ||
| HK1206028A1 (en) | Phenicol antibacterials | |
| JP2016135110A5 (enExample) | ||
| WO2016059019A3 (en) | Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| JP2016540019A5 (enExample) | ||
| CY1121986T1 (el) | Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της | |
| AU2014233420A8 (en) | Fine dry particulate retinoid active agent compositions and topical formulations including the same | |
| HK1209371A1 (en) | Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same | |
| EP2978428A4 (en) | STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| JP2019094312A5 (enExample) | ||
| JP2014500802A5 (enExample) | ||
| JP2019523305A5 (enExample) | ||
| WO2015095659A3 (en) | Indirubin solid dispersion composition | |
| WO2013024494A3 (en) | Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone | |
| WO2016015055A8 (en) | Colon cleansing compositions | |
| JP2014510253A5 (enExample) | ||
| HK1245155A1 (zh) | 制备去氧肾上腺素树脂酸盐颗粒的方法；去氧肾上腺素树脂酸盐颗粒；以及去氧肾上腺素树脂酸盐颗粒在药物制剂中的用途 | |
| HK1203379A1 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF |